Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

RA Capital has launched Swiftbridge, a new initiative designed to give its biotech portfolio companies structured access to China’s clinical trial ecosystem. Introduced in mid-2025, the program removes a key bottleneck in global drug development by simplifying entry into China’s
A U.S. federal jury in Boston has ruled against Takeda in a pay-for-delay antitrust case involving its constipation drug Amitiza, forcing the company to book a $2.5 billion legal provision and swing to a FY2025 net loss. The decision marks
At BioSpace’s NextGen 2026 discussion, leading biotech executives from the United States and China highlighted a growing strategic divide in pharmaceutical innovation. The conversation revealed how artificial intelligence is now accelerating drug discovery and clinical decision-making, while simultaneously exposing weaknesses
BioSpace’s NextGen 2026 biotech leaders highlighted at a recent industry discussion how artificial intelligence is rapidly reshaping drug development while exposing a critical weakness in pharmaceutical innovation: data quality. Executives from emerging biotech companies emphasized that while AI accelerates discovery
Aragen has completed technology transfer and initiated first commercial-scale GMP manufacturing runs for Renaissance Pharma’s lead monoclonal antibody Daretabart at its Bengaluru facility in India. The company originally developed the cell line and early process at its Morgan Hill site
In a recent interview with Christopher Cole of Pharmaceutical Technology, Henrik Johanning from Epista Life Science discussed how pharmaceutical manufacturing and regulatory systems in Europe are shifting from 2025 into 2026. He explained that quality risk management, digital GMP, and
In September 2025, President Donald Trump called for stricter enforcement of existing rules on direct-to-consumer (DTC) prescription drug advertising by the U.S. Food and Drug Administration (FDA). Around the same period, HHS Secretary Robert F. Kennedy Jr. also criticized pharmaceutical
A recent survey by the Pistoia Alliance at the Clinical Trials Technology Congress (CTTC) in London shows that trust issues and regulatory uncertainty continue to slow artificial intelligence adoption in clinical trials. Although AI already delivers early value in clinical
The FDA is urging pharmaceutical companies to re-examine decades of clinical and real-world data using AI and advanced analytics to identify new uses for existing drugs. Published on May 29, 2026, this initiative highlights how legacy datasets may still hold
A major shift is underway in pharmaceutical manufacturing as companies move toward hybrid cloud infrastructure, advanced analytics, and digital quality systems. Speaking on the industry's evolving landscape, Mike Hennessy Jr. of MJH Life Sciences highlighted how hybrid cloud architectures, statistical